Alterity Therapeutics, a development stage enterprise, has successfully conducted an Extraordinary General Meeting (EGM) on April 12, 2024, where all resolutions were passed by poll. The meeting, which took place in Melbourne, Australia, and was also relevant to the company's operations in San Francisco, USA, saw the approval of various undisclosed resolutions. The results of the EGM are in compliance with the ASX Listing Rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001. Detailed proxy and voting results have been provided in accordance with regulatory requirements. The company, which is listed on both the ASX and NASDAQ, has incorporated the report into its SEC filings, including its Registration Statements on Forms S-8 and F-3.

Alterity Therapeutics, a development stage enterprise, has successfully conducted an Extraordinary General Meeting (EGM) on April 12, 2024, where all resolutions were passed by poll. The meeting, which took place in Melbourne, Australia, and was also relevant to the company's operations in San Francisco, USA, saw the approval of various undisclosed resolutions. The results of the EGM are in compliance with the ASX Listing Rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001. Detailed proxy and voting results have been provided in accordance with regulatory requirements. The company, which is listed on both the ASX and NASDAQ, has incorporated the report into its SEC filings, including its Registration Statements on Forms S-8 and F-3.